A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06788652
Status
Recruiting
Apply to this trial

Conditions

  • Mantle Cell Lymphoma (MCL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lisocabtagene maraleucel — BIOLOGICAL
    According to US Prescribing Information

Study Details

The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).

Key Dates

Start date
Feb 4, 2025
Status verified
Feb 2025
Primary completion
Sep 30, 2044
Completion
Sep 30, 2044

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Participants treated with lisocabtagene maraleucel

Primary Outcome Measure

Adverse events (AEs) [ Time Frame: Up to 15 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Center for International Blood and Marrow Transplant Research (CIBMTR)MilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By research site
Center for International Blood and Marrow Transplant Research (CIBMTR)· Milwaukee, WI

Related Studies